MMRi67 is a potent E3 ligase inhibitor of the MDM2-MDM4 E3 complex, inhibits RING-RING interaction of MDM4 and MDM2B with Kd of 896 nM.

MMRi71 is a small molecule inhibitor of the E3 ligase activity of MDM2-MDM4, and an inducer of MDM4 and FTH1 dual protein degradation and p53-independent apoptosis in leukemia cells.

Morncide (Morn3 (222-237)) is a cell-penetrating, 16-AA Morn3-targeting peptide that disrupts the interaction between p53 and Morn3-mediated complex, Morncide peptide stabilizes and reactivates p53 in cancer cells.

NSC146109 (XI-011) is a small-molecule p53 activator, induces apoptosis of breast cancer cells through inhibiting MDMX (MDM4) expression.

ReACp53 is a cell-penetrating 17-residue peptide designed to inhibit p53 amyloid formation, rescues p53 function in cancer cell lines.

UC2288 is a small molecule p21 inhibitor, attenuates p21 protein abundance at 10 µM, independently of p53 activity and at the level of transcription or post-transcription.

UCI-LC0019 is a specific small molecule that restores mutant p53 activity by targeting the cryptic L1/S3 pocket of p53, directly binds to mutant p53 and restores wild-type-like conformation of mutant p53R175H.

UCI-LC0023 is a small molecule that restores mutant p53 activity by targeting the cryptic L1/S3 pocket of p53, directly binds to mutant p53 and restores wild-type-like conformation of mutant p53R175H.

AC-003 is a novel oral small-molecule inhibitor of receptor interacting protein kinase 1(RIPK1) and has the potential for treating idiopathic pulmonary fibrosis.

aYM155 is a brain-penetrating prodrug form of YM155 (Cat. PC-42439, potent survivin inhibitor), displays potent cell killing activity against a broad panel of patient-derived GBM cancer stem-like cells (IC50=0.7-10 nM).

cRIPGBM (RIPGBM derivative cRIPGBM, RIPGBM-18) is a metabolite of RIPGBM induces apoptosis in GBM CSCs (EC50=68 nM in GBM 1 cells) by interacting with RIPK2 (Kd=2.3 uM).

Flizasertib is a potent, selective RIP1 kinase (RIPK1) inhibitor with potential for treating prophylaxis.

GNE-684 is a potent, cross-species, specific RIP1 kinase (RIPK1) inhibitor with IC50 of 21, 189 and 691 nM for human, mouse and rat RIP1, respectively.

GSK2593074A (GSK'074, GSK-2593074A) is novel potent, selective RIP1/RIP3 kinase dual inhibitor, directly binds to RIP1 and RIP3 with Kd of 130 and 12 nM, respectively.

Oditrasertib is a potent, selective RIPK1 inhibitor.

Zharp1-211 is a potent, selective, type II inhibitor of RIPK1 kinase with IC50 of 53 nM and binding Kd of 8.7 nM.

Zharp2-1 is a novel potent, selective RIPK2 inhibitor with IC50 of 38.5 nM in ADP-Glo kinase assay, effectively blocks RIPK2 kinase function and NOD-mediated NF-κB/MAPK activation.

JS-017 (JS017) is a small molecule degrader of N-retinylidene-N-retinylethanolamine (A2E), one of the components of lipofuscin, degrades A2E-BDP from ARPE-19 cells with IC50 of 3.239 uM.

RH1115 is a small molecule activator and inducer of autophagy targeting Lamin A/C and LAMP1, induces changes to LAMP1 vesicle properties and alters lysosome positioning.

YTK-2205 (YTK2205) is a small molecule p62 agonist targeting ZZ domain, induces selective autophagy activation, YTK-2205 augments the translocation of p62 to mitochondria, targeting their lysosomal degradation.

DC-ATG4in is a small molecule autophagy related 4B (ATG4B) inhibitor, directly binds to ATG4B and inhibits its enzyme activity with IC50 of 3.08 uM, DC-ATG4in is an autophagy inhibitor.

BIIB122 (DNL151) is a potent, selective, CNS-penetrant LRRK2 inhibitor.